× Patient monitoring and counseling*
Safety remains at the heart of what we do. To support education and monitoring for patients with wet AMD, please see the following counseling guidance as well as a resource guide below.
BEOVU is contraindicated in1:
- Patients with ocular or periocular infections
- Patients with active intraocular inflammation
- Patients with known hypersensitivity to brolucizumab or any of the excipients in BEOVU
- Hypersensitivity reactions may manifest as rash, pruritus, urticaria, erythema, or severe intraocular inflammation
Guidance1:
- Advise patients there is a risk of developing endophthalmitis, retinal detachment, retinal vasculitis, and/or retinal vascular occlusion in the days following BEOVU administration
- Reports of retinal vasculitis and/or retinal vascular occlusion typically occurred in the presence of intraocular inflammation
- Patients should be monitored for increased intraocular pressure immediately following the intravitreal injection. Monitoring may include checking for perfusion of the optic nerve head or tonometry
Patients should be instructed to seek immediate care from their ophthalmologist if they experience any of the following symptoms or any change in vision1:
- Increased light sensitivity
- Floaters
- Pain in their eye
- Decrease in vision
- Redness on the white part of the eye
We've developed a guide to help your patients monitor their vision at home and know what to do if they experience changes in vision.
*This is a subset of information from the Prescribing Information. As always, please review the full Prescribing Information.
Please see the Important Safety Information for BEOVU.